Trial
NCT02154529
Study of the Combination of KD019 and Trastuzumab in Subjects With HER2-Positive Metastatic Breast Cancer
Phase ITERMINATEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
Kadmon Corporation, LLC
Collaborators
—
Condition
HER-2 Positive Breast Cancer
Intervention
Tesevatinib
Why stopped
Sponsor closed the study due to lack of response.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2022-04-27